Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats

Journal of Veterinary Internal Medicine

Volumn 20, Issue 6, 2006, Pages 1370-1375

  McEntee, Margaret C ^a   Rassnick, K M ^a   Bailey, D B ^a   Balkman, C E ^a   Flanagan, J L ^b   Beaulieu, B B ^b   Zgola, M M ^a   Lewis, L D ^b   Page, R L ^a  

^a Department of Obstetrics Gynecology   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cats; Chemotherapy; Clinical trial; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; DOCETAXEL; TAXOID;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; CAT; CAT DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; MALE; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAT DISEASES; CATS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; MALE; NEOPLASMS; TAXOIDS;

CANIS FAMILIARIS;

EID: 33845706632     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[1370:PIAPEO]2.0.CO;2     Document Type: Article

References (20)

1. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (taxotere®): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995;6:339-368.
2. Masini E, Planchenault J, Pessiardi F, et al. Histamine-releasing properties of polysorbate 80 in vitro and in vivo: Correlation with its hypotensive action in the dog. Agents Action 1985;16:470-477.
3. Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160-1166.
4. McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2003;1:105-112.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
6. van Asperen J, van Tellingen O, Beijnen JH. The pharmacological role of p-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37:429-435.
7. van Zuylen L, Verweij J, Nooter K, et al. Role of intestinal p-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6:2598-2603.
8. McEntee MC, Rassnick KM, Lewis LD, et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Am J Vet Res 2004;67:1057-1062.
9. World Health Organization, Update 2001: Recommendations for grading of acute and subacute toxicities. Available at: http://www.fda.gov/cder/cancer/ toxicityframe.htm. Accessed November 2005.
10. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783:231-236.
11. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:2669-2671.
12. Poirier VJ, Hershey AE, Burgess KE, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004;18:219-222.
13. Kuppens EILM, Bosch TM, van Maanen MJ, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005;55:72-78.
14. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-1077.
15. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19:163-169.
16. Baker SD, Zhao M, Lee CKK, et al. Comparative pharmacokinetics of weekly and every-three-week docetaxel. Clin Cancer Res 2004;10:1976-1983.
17. Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-4198.
18. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;13:286-292.
19. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl cancer research network phase II trial. J Clin Oncol 2001;19:3500-3505.
20. Maisano R, Mare M, Zavettieri M, et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003;23:1923-1926.